DE60236218D1 - CCR5 Antagonisten verwendbar für die Behandlung von Aids - Google Patents

CCR5 Antagonisten verwendbar für die Behandlung von Aids

Info

Publication number
DE60236218D1
DE60236218D1 DE60236218T DE60236218T DE60236218D1 DE 60236218 D1 DE60236218 D1 DE 60236218D1 DE 60236218 T DE60236218 T DE 60236218T DE 60236218 T DE60236218 T DE 60236218T DE 60236218 D1 DE60236218 D1 DE 60236218D1
Authority
DE
Germany
Prior art keywords
aids
treatment
antagonists useful
ccr5 antagonists
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236218T
Other languages
English (en)
Inventor
Michael W Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60236218D1 publication Critical patent/DE60236218D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE60236218T 2001-03-29 2002-03-27 CCR5 Antagonisten verwendbar für die Behandlung von Aids Expired - Lifetime DE60236218D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
DE60236218D1 true DE60236218D1 (de) 2010-06-10

Family

ID=23070981

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60236218T Expired - Lifetime DE60236218D1 (de) 2001-03-29 2002-03-27 CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60204951T Expired - Lifetime DE60204951T2 (de) 2001-03-29 2002-03-27 Ccr5 antagonisten verwendbar für die behandlung von aids

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60204951T Expired - Lifetime DE60204951T2 (de) 2001-03-29 2002-03-27 Ccr5 antagonisten verwendbar für die behandlung von aids

Country Status (30)

Country Link
US (5) US6720325B2 (de)
EP (2) EP1591444B1 (de)
JP (2) JP4248251B2 (de)
KR (1) KR100613528B1 (de)
CN (1) CN100519554C (de)
AR (1) AR033452A1 (de)
AT (2) ATE299139T1 (de)
AU (1) AU2002255947B8 (de)
BR (1) BR0208398A (de)
CA (1) CA2442227C (de)
CZ (1) CZ20032636A3 (de)
DE (2) DE60236218D1 (de)
DK (1) DK1373256T3 (de)
ES (2) ES2242856T3 (de)
HK (2) HK1057363A1 (de)
HU (1) HUP0400349A3 (de)
IL (1) IL157551A0 (de)
MX (1) MXPA03008853A (de)
MY (1) MY128609A (de)
NO (1) NO326349B1 (de)
NZ (1) NZ527768A (de)
PE (1) PE20020996A1 (de)
PL (1) PL364560A1 (de)
PT (1) PT1373256E (de)
RU (1) RU2316553C2 (de)
SI (1) SI1373256T1 (de)
SK (1) SK287521B6 (de)
TW (1) TWI237638B (de)
WO (1) WO2002079194A1 (de)
ZA (1) ZA200307474B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079194A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Ccr5 antagonists useful for treating aids
BR0210733A (pt) 2001-07-02 2004-07-20 Astrazeneca Ab Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
ATE410426T1 (de) * 2002-12-13 2008-10-15 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JP4757802B2 (ja) * 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
ES2324224T3 (es) * 2004-02-05 2009-08-03 Schering Corporation Derivados de piperidina que se pueden utilizar como antagonistas ccr3.
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
MXPA06011722A (es) 2004-04-13 2007-01-25 Incyte Corp Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina.
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1833817B1 (de) * 2005-01-06 2010-10-13 Schering Corporation Synthese von ccr5 rezeptor antagonisten
EP1836190A2 (de) * 2005-01-06 2007-09-26 Schering Corporation Herstellung pharmazeutischer salze aus piperazin-verbindungen
CN101133050A (zh) * 2005-02-23 2008-02-27 先灵公司 用作趋化因子受体抑制剂的哌啶基哌啶
CN101163695A (zh) * 2005-02-23 2008-04-16 先灵公司 用作趋化因子受体抑制剂的哌啶基哌嗪衍生物
RU2008105987A (ru) 2005-07-21 2009-08-27 Астразенека Аб (Se) Новые пиперидиновые производные
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CA2221507C (en) 1995-06-07 2008-01-15 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein in absorbent article
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (de) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkane als CCR5-Modulatoren
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
ES2246233T3 (es) * 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
WO2002079194A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Ccr5 antagonists useful for treating aids

Also Published As

Publication number Publication date
CN100519554C (zh) 2009-07-29
DE60204951T2 (de) 2006-05-11
US7060701B2 (en) 2006-06-13
US20060063771A1 (en) 2006-03-23
US20040157854A1 (en) 2004-08-12
AU2002255947B8 (en) 2005-11-17
WO2002079194A1 (en) 2002-10-10
EP1373256B1 (de) 2005-07-06
CN1547580A (zh) 2004-11-17
EP1591444A1 (de) 2005-11-02
AR033452A1 (es) 2003-12-17
RU2316553C2 (ru) 2008-02-10
KR20030083014A (ko) 2003-10-23
EP1591444B1 (de) 2010-04-28
AU2002255947B2 (en) 2005-10-27
KR100613528B1 (ko) 2006-08-16
BR0208398A (pt) 2004-06-15
HUP0400349A2 (hu) 2004-12-28
US7098213B2 (en) 2006-08-29
NZ527768A (en) 2005-03-24
MY128609A (en) 2007-02-28
IL157551A0 (en) 2004-03-28
PE20020996A1 (es) 2002-11-01
TWI237638B (en) 2005-08-11
CZ20032636A3 (cs) 2003-12-17
US20050059666A1 (en) 2005-03-17
MXPA03008853A (es) 2003-12-04
EP1373256A1 (de) 2004-01-02
US6900211B2 (en) 2005-05-31
CA2442227C (en) 2008-10-28
SK287521B6 (sk) 2010-12-07
NO20034311D0 (no) 2003-09-26
US20050143390A1 (en) 2005-06-30
US7008946B2 (en) 2006-03-07
JP2008074862A (ja) 2008-04-03
DK1373256T3 (da) 2005-10-10
NO20034311L (no) 2003-11-26
HK1083505A1 (en) 2006-07-07
PL364560A1 (en) 2004-12-13
US20030008877A1 (en) 2003-01-09
HK1057363A1 (en) 2004-04-02
SI1373256T1 (sl) 2005-12-31
ZA200307474B (en) 2004-12-24
ATE466009T1 (de) 2010-05-15
ATE299139T1 (de) 2005-07-15
ES2342942T3 (es) 2010-07-19
CA2442227A1 (en) 2002-10-10
RU2003131879A (ru) 2005-05-10
NO326349B1 (no) 2008-11-17
DE60204951D1 (de) 2005-08-11
HUP0400349A3 (en) 2010-03-29
US6720325B2 (en) 2004-04-13
PT1373256E (pt) 2005-11-30
JP4248251B2 (ja) 2009-04-02
JP2004525157A (ja) 2004-08-19
ES2242856T3 (es) 2005-11-16
SK11962003A3 (sk) 2004-03-02

Similar Documents

Publication Publication Date Title
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE50214540D1 (de) Stanz bei der behandlung von wunden
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE602004008631D1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE276262T1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
DE50209798D1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition